These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 19151767)

  • 1. Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells.
    Finkbeiner MR; Astanehe A; To K; Fotovati A; Davies AH; Zhao Y; Jiang H; Stratford AL; Shadeo A; Boccaccio C; Comoglio P; Mertens PR; Eirew P; Raouf A; Eaves CJ; Dunn SE
    Oncogene; 2009 Mar; 28(11):1421-31. PubMed ID: 19151767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy.
    Stratford AL; Habibi G; Astanehe A; Jiang H; Hu K; Park E; Shadeo A; Buys TP; Lam W; Pugh T; Marra M; Nielsen TO; Klinge U; Mertens PR; Aparicio S; Dunn SE
    Breast Cancer Res; 2007; 9(5):R61. PubMed ID: 17875215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1.
    Astanehe A; Finkbeiner MR; Hojabrpour P; To K; Fotovati A; Shadeo A; Stratford AL; Lam WL; Berquin IM; Duronio V; Dunn SE
    Oncogene; 2009 Jun; 28(25):2406-18. PubMed ID: 19430491
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.
    De Bacco F; Luraghi P; Medico E; Reato G; Girolami F; Perera T; Gabriele P; Comoglio PM; Boccaccio C
    J Natl Cancer Inst; 2011 Apr; 103(8):645-61. PubMed ID: 21464397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells.
    Dhillon J; Astanehe A; Lee C; Fotovati A; Hu K; Dunn SE
    Oncogene; 2010 Nov; 29(47):6294-300. PubMed ID: 20802512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2.
    Wu J; Lee C; Yokom D; Jiang H; Cheang MC; Yorida E; Turbin D; Berquin IM; Mertens PR; Iftner T; Gilks CB; Dunn SE
    Cancer Res; 2006 May; 66(9):4872-9. PubMed ID: 16651443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RNA interference reveals that ligand-independent met activity is required for tumor cell signaling and survival.
    Shinomiya N; Gao CF; Xie Q; Gustafson M; Waters DJ; Zhang YW; Vande Woude GF
    Cancer Res; 2004 Nov; 64(21):7962-70. PubMed ID: 15520203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells.
    Stratford AL; Fry CJ; Desilets C; Davies AH; Cho YY; Li Y; Dong Z; Berquin IM; Roux PP; Dunn SE
    Breast Cancer Res; 2008; 10(6):R99. PubMed ID: 19036157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice.
    Lee C; Dhillon J; Wang MY; Gao Y; Hu K; Park E; Astanehe A; Hung MC; Eirew P; Eaves CJ; Dunn SE
    Cancer Res; 2008 Nov; 68(21):8661-6. PubMed ID: 18974106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer.
    Kashihara M; Azuma K; Kawahara A; Basaki Y; Hattori S; Yanagawa T; Terazaki Y; Takamori S; Shirouzu K; Aizawa H; Nakano K; Kage M; Kuwano M; Ono M
    J Thorac Oncol; 2009 Sep; 4(9):1066-74. PubMed ID: 19648825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Y-box binding protein 1 is up-regulated in proliferative breast cancer and its inhibition deregulates the cell cycle.
    Yu YN; Yip GW; Tan PH; Thike AA; Matsumoto K; Tsujimoto M; Bay BH
    Int J Oncol; 2010 Aug; 37(2):483-92. PubMed ID: 20596676
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival.
    Lutterbach B; Zeng Q; Davis LJ; Hatch H; Hang G; Kohl NE; Gibbs JB; Pan BS
    Cancer Res; 2007 Mar; 67(5):2081-8. PubMed ID: 17332337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Krüppel-like factor 5 promotes breast cell proliferation partially through upregulating the transcription of fibroblast growth factor binding protein 1.
    Zheng HQ; Zhou Z; Huang J; Chaudhury L; Dong JT; Chen C
    Oncogene; 2009 Oct; 28(42):3702-13. PubMed ID: 19668233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scatter factor stimulates tumor growth and tumor angiogenesis in human breast cancers in the mammary fat pads of nude mice.
    Lamszus K; Jin L; Fuchs A; Shi E; Chowdhury S; Yao Y; Polverini PJ; Laterra J; Goldberg ID; Rosen EM
    Lab Invest; 1997 Mar; 76(3):339-53. PubMed ID: 9121117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. E2F-HDAC complexes negatively regulate the tumor suppressor gene ARHI in breast cancer.
    Lu Z; Luo RZ; Peng H; Huang M; Nishmoto A; Hunt KK; Helin K; Liao WS; Yu Y
    Oncogene; 2006 Jan; 25(2):230-9. PubMed ID: 16158053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1).
    Reipas KM; Law JH; Couto N; Islam S; Li Y; Li H; Cherkasov A; Jung K; Cheema AS; Jones SJ; Hassell JA; Dunn SE
    Oncotarget; 2013 Feb; 4(2):329-45. PubMed ID: 23593654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The phosphoinositide-dependent kinase-1 inhibitor 2-amino-N-[4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-acetamide (OSU-03012) prevents Y-box binding protein-1 from inducing epidermal growth factor receptor.
    To K; Zhao Y; Jiang H; Hu K; Wang M; Wu J; Lee C; Yokom DW; Stratford AL; Klinge U; Mertens PR; Chen CS; Bally M; Yapp D; Dunn SE
    Mol Pharmacol; 2007 Sep; 72(3):641-52. PubMed ID: 17595327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells.
    Sutherland BW; Kucab J; Wu J; Lee C; Cheang MC; Yorida E; Turbin D; Dedhar S; Nelson C; Pollak M; Leighton Grimes H; Miller K; Badve S; Huntsman D; Blake-Gilks C; Chen M; Pallen CJ; Dunn SE
    Oncogene; 2005 Jun; 24(26):4281-92. PubMed ID: 15806160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The strand separation and nuclease activities associated with YB-1 are dispensable for cisplatin resistance but overexpression of YB-1 in MCF7 and MDA-MB-231 breast tumor cells generates several chemoresistance signatures.
    Guay D; Evoy AA; Paquet E; Garand C; Bachvarova M; Bachvarov D; Lebel M
    Int J Biochem Cell Biol; 2008; 40(11):2492-507. PubMed ID: 18571458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased nuclear localization of transcription factor Y-box binding protein 1 accompanied by up-regulation of P-glycoprotein in breast cancer pretreated with paclitaxel.
    Fujita T; Ito K; Izumi H; Kimura M; Sano M; Nakagomi H; Maeno K; Hama Y; Shingu K; Tsuchiya S; Kohno K; Fujimori M
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8837-44. PubMed ID: 16361573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.